Label-free digital pathology in cooperation with biophysics in PRODI
The aim of this study is to establish a label-free digital pathology with IR imaging for a fast, reliable and accurate diagnosis of prostate cancer. This method is based on spectral IR imaging of prostate tissue obtained during transurethral resection/laser enucleation of the prostate (TUR-P/TULEP). After the initial training phase, label-free digital histopathology will be applied to prostate tissue obtained during a punch biopsy for suspected prostate cancer.
ColoPredict Plus 2.0 Register study
Retrospective and prospective recording of the role of MSI and KRAS for the prognosis of stage I to III colon cancer; identification of a marker panel for the therapy of CRC.
The Colopredict Plus Registry will retrospectively and prospectively enrol patients with stage I to III colon cancer. The primary objective of the study is to determine the role of microsatellite instability (MSI) in combination with a KRAS mutation in the prognosis of stage II colon cancer without clinical risk factors. For this purpose, MSI and KRAS will be determined in tumour tissue samples of the recruited patients and clinical and histopathological data of the patients will be documented in parallel. The primary target parameter is relapse-free survival after 5 years (combined endpoint of relapse and death from any cause).
FTIR / Raman spectroscopy
Contact & Employees
Dr. med. H. Jütte
Dr. rer. nat. B. Flott-Rahmel
Dr. rer. nat. B. Verdoodt
Dr. rer. nat J. Vornweg
Dr. rer. nat S. Wisser
Dr. J. Christmann
M. Sc. C. Hippert